aTyr Pharma Shares Drop 80% After Lung Disease Drug Fails in Phase 3 Trial
TL;DR Summary
aTyr Pharma's experimental drug efzofitimod failed to meet its primary goal in a late-stage trial for pulmonary sarcoidosis, causing its shares to plummet over 80% to a record low, though the company sees potential benefits and plans to discuss next steps with the FDA.
Topics:business#atyr-pharma#drug-trial-failure#efzofitimod#health#lung-disease#pulmonary-sarcoidosis
- aTyr hits record low as lung disease drug fails in late-stage trial Reuters
- aTyr flunks phase 3 lung disease trial, deflating stock, but still plans talks with FDA Fierce Biotech
- 1 Small-Cap Biotech Stock Poised for a Breakout The Motley Fool
- BREAKING: aTyr Pharma Shares Plummet 80%; Investors Should GlobeNewswire
- Atyr phase III steroid-taper off; efzofitimod PS odds narrower? BioWorld MedTech
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
87%
329 → 44 words
Want the full story? Read the original article
Read on Reuters